Imugene Limited
IUGNF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $4,397 | $4,970 | $11,778 | $12,970 |
| % Growth | -11.5% | -57.8% | -9.2% | – |
| Cost of Goods Sold | $0 | $5,840 | $2,204 | $2,407 |
| Gross Profit | $4,397 | $4,970 | $9,574 | $10,563 |
| % Margin | 100% | 100% | 81.3% | 81.4% |
| R&D Expenses | $46,691 | $86,885 | $30,865 | $36,612 |
| G&A Expenses | $27,770 | $59,907 | $17,766 | $12,097 |
| SG&A Expenses | $27,770 | $59,907 | $18,225 | $12,432 |
| Sales & Mktg Exp. | $0 | $0 | $507 | $335 |
| Other Operating Expenses | $876 | $11,896 | $2,203 | $1,629 |
| Operating Expenses | $75,337 | $158,688 | $51,293 | $50,673 |
| Operating Income | -$70,940 | -$153,718 | -$39,767 | -$37,941 |
| % Margin | -1,613.5% | -3,092.9% | -337.6% | -292.5% |
| Other Income/Exp. Net | $1,919 | -$578 | $1,852 | $72 |
| Pre-Tax Income | -$69,022 | -$154,296 | -$37,915 | -$37,869 |
| Tax Expense | $0 | -$4,615 | -$11,742 | -$12,614 |
| Net Income | -$69,022 | -$149,681 | -$37,915 | -$37,869 |
| % Margin | -1,569.8% | -3,011.7% | -321.9% | -292% |
| EPS | -0.32 | -0.72 | -0.21 | -0.23 |
| % Growth | 55.6% | -242.9% | 8.7% | – |
| EPS Diluted | -0.32 | -0.72 | -0.21 | -0.23 |
| Weighted Avg Shares Out | 218,704 | 208,494 | 184,579 | 165,800 |
| Weighted Avg Shares Out Dil | 218,703 | 208,494 | 184,579 | 165,800 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,919 | $4,516 | $1,880 | $192 |
| Interest Expense | $0 | $478 | $27 | $14 |
| Depreciation & Amortization | $2,641 | $5,840 | $2,204 | $2,407 |
| EBITDA | -$67,423 | -$147,978 | -$47,425 | -$35,296 |
| % Margin | -1,533.5% | -2,977.4% | -402.7% | -272.1% |